Literature DB >> 23392850

Acknowledging the relevance of cognitive changes in cancer patients: perspectives of oncology practitioners in Asia.

Yin Ting Cheung1, Maung Shwe, Earl Hsien Jie Tan, Wai Keung Chui, Raymond Ng, Alexandre Chan.   

Abstract

PURPOSE: Previous studies have suggested that cognitive impairment can affect cancer patients' health-related quality of life (HRQoL) and daily functioning. This study investigated oncology practitioners' perceptions of the relevance, effects, and causes of such cognitive changes in cancer patients, and their awareness of coping strategies.
METHODS: Oncology practitioners completed a self-administered cross-sectional survey. Practitioners were recruited from four major cancer centers in Singapore and Thailand, and through a regional cancer meeting that took place in Singapore in September 2011.
RESULTS: The sample (n = 193) consisted of nurses (51.3 %), oncologists (35.2 %), and pharmacists (13.5 %). Cognitive changes were frequently observed among cancer patients, particularly in the domains of memory (77.1 %) and concentration (74.6 %). The majority (86.5 %) of respondents agreed that cognitive changes adversely effected patients' HRQoL. The majority (65.3 %) of the respondents also recognized the need to implement routine neuropsychological assessments in clinical settings. The following factors were perceived as contributing to cognitive changes: aging (77.6 %), cancer-related fatigue (65.2 %), and anxiety (61.2 %). Compared with other healthcare professionals, oncologists were less likely to agree that chemotherapy was a major contributing factor to cognitive changes (25.0 % vs. 9.8 %, p = 0.038). Psychosocial support and the use of complementary alternative medicines (CAM) were identified as coping strategies for cognitive changes.
CONCLUSIONS: Healthcare professionals do not perceive a uniform set of contributing factors to cognitive impairment among cancer patients, although they all acknowledge that cancer patients' experience of cognitive impairment is a relevant issue. IMPLICATIONS FOR CANCER SURVIVORS: It is important to equip clinicians with the knowledge necessary for monitoring and managing the cognitive disturbances and psychological distress experienced by at risk patients in a clinical setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23392850     DOI: 10.1007/s11764-012-0256-4

Source DB:  PubMed          Journal:  J Cancer Surviv        ISSN: 1932-2259            Impact factor:   4.442


  55 in total

Review 1.  Review of recent studies on interventions for cognitive deficits in patients with cancer.

Authors:  Karin Gehring; Jan Anne Roukema; Margriet M Sitskoorn
Journal:  Expert Rev Anticancer Ther       Date:  2012-02       Impact factor: 4.512

Review 2.  Chemotherapy and cognitive impairment: treatment options.

Authors:  J E Fardell; J Vardy; I N Johnston; G Winocur
Journal:  Clin Pharmacol Ther       Date:  2011-08-03       Impact factor: 6.875

3.  Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.

Authors:  Kelly-Anne Phillips; Julie Aldridge; Karin Ribi; Zhuoxin Sun; Alastair Thompson; Vernon Harvey; Beat Thürlimann; Fatima Cardoso; Olivia Pagani; Alan S Coates; Aron Goldhirsch; Karen N Price; Richard D Gelber; Jürg Bernhard
Journal:  Breast Cancer Res Treat       Date:  2010-11-03       Impact factor: 4.872

Review 4.  Cognitive function in breast cancer survivors.

Authors:  Janette Vardy
Journal:  Cancer Treat Res       Date:  2009

Review 5.  Subjective cognitive dysfunction in breast cancer patients: a systematic review.

Authors:  Marleen J J Pullens; Jolanda De Vries; Jan A Roukema
Journal:  Psychooncology       Date:  2010-11       Impact factor: 3.894

6.  Changes in perceived attentional function in women following breast cancer surgery.

Authors:  Mei-Ling Chen; Christine Miaskowski; Li-Ni Liu; Shin-Cheh Chen
Journal:  Breast Cancer Res Treat       Date:  2011-09-07       Impact factor: 4.872

7.  Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study.

Authors:  Kerstin Hermelink; Michael Untch; Michael P Lux; Rolf Kreienberg; Thomas Beck; Ingo Bauerfeind; Karin Münzel
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

Review 8.  Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions.

Authors:  Christian J Nelson; Nina Nandy; Andrew J Roth
Journal:  Palliat Support Care       Date:  2007-09

9.  Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve.

Authors:  Tim A Ahles; Andrew J Saykin; Brenna C McDonald; Yuelin Li; Charlotte T Furstenberg; Brett S Hanscom; Tamsin J Mulrooney; Gary N Schwartz; Peter A Kaufman
Journal:  J Clin Oncol       Date:  2010-09-13       Impact factor: 44.544

10.  Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response.

Authors:  Nelli Boykoff; Mona Moieni; Saskia Karen Subramanian
Journal:  J Cancer Surviv       Date:  2009-09-16       Impact factor: 4.442

View more
  3 in total

1.  The perceptions of Australian oncologists about cognitive changes in cancer survivors.

Authors:  Kate Smidt; Lynette Mackenzie; Haryana Dhillon; Janette Vardy; Joanne Lewis; Siew Yim Loh
Journal:  Support Care Cancer       Date:  2016-06-20       Impact factor: 3.603

2.  Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications.

Authors:  Maryam Hafsah Selamat; Siew Yim Loh; Lynette Mackenzie; Janette Vardy
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

3.  Australian oncology health professionals' knowledge, perceptions, and clinical practice related to cancer-related cognitive impairment and utility of a factsheet.

Authors:  Sharon He; Chloe Yi Shing Lim; Haryana M Dhillon; Joanne Shaw
Journal:  Support Care Cancer       Date:  2022-02-05       Impact factor: 3.359

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.